Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
Puerto Rico: above-average open trial sites
8 of 14 in-state trials are recruiting (57%); above the 37% national average by 20 percentage points, with Phase 3 weight.
According to ClinicalTrials.gov-derived indexes, Puerto Rico sits in the lower half of US states by in-state trial count (#52 of 52 states by registered in-state trial count).
Puerto Rico: 14 US clinical trials with in-state sites, 8 recruiting.
Puerto Rico has 14 registered US clinical trials with a study site in-state, 8 of them currently recruiting (above the 37% national average by 20 percentage points). 2 of these trials are in Phase 3 (late-stage) and 1 in Phase 2. The most frequently studied condition in Puerto Rico is Cancer of Pancreas, with 2 linked trials.
Thin-tail state archive
Puerto Rico is in the lower half of states by in-state trial count. Treat this page as a compact local index, browse recruiting trials or methodology rather than expecting hub-scale coverage.
Above-average open, later-stage tilt
Puerto Rico currently lists 8 recruiting sites across 14 in-state trials (57% open): above the 37% national average by 20 percentage points, so open slots are denser than the registry-wide mix.
- 8
- recruiting now (above-average share)
- 57%
- open vs national baseline
- 2
- Phase 3 rows in this footprint
- 2
- top: Cancer of Pancreas
Recruiting share is above the 37% national average by 20 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Puerto Rico on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Puerto Rico open-enrollment share sits above the national baseline.
8 of 14 in-state trials (57.1%) are recruiting, against 37% nationally (+20.1 percentage points). Counts include every study with at least one recorded site in the state.
-
San Juan dominates Puerto Rico's trial geography.
San Juan lists 10 of 14 in-state trials (71.4%) across 9 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Cancer of Pancreas is the most-studied condition in Puerto Rico.
2 of 14 in-state trials (14.3%) list Cancer of Pancreas. That is a local concentration figure, not a national disease ranking.
-
One sponsor accounts for a large share of Puerto Rico trials.
HUYABIO International appears on 2 of 14 in-state trials (14.3%). Sponsor identity is as filed on ClinicalTrials.gov.
-
3 Puerto Rico trials carry a completed status.
3 of 14 (21.4%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Recruiting | 8 |
| Completed | 3 |
| Active | 3 |
By Phase
| Phase | Trial count |
|---|---|
| NA | 6 |
| Phase 1 | 5 |
| Phase 3 | 2 |
| Phase 2 | 1 |
Top Conditions
Top Sponsors
Where trials run in Puerto Rico
San Juan is the only Puerto Rico city with five or more listed trials, carrying 10 of the state's 14 across 9 named sites.
| City | Trials | Listed sites |
|---|---|---|
| San Juan | 10 | 9 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-07-11.
Where Puerto Rico enrollment beats the national open share
Sites cluster almost entirely in San Juan: 10 of Puerto Rico's 14 indexed trials list a site there, across 9 named locations, and no other city reaches five.
Phase mix: 2 Phase 3 vs 1 Phase 2 (later-stage heavy).
Top condition: Cancer of Pancreas (2 trials); top sponsor HUYABIO International (2).
How above-average open share is computed
Recruiting share = in-state Recruiting trials ÷ all in-state trials (8 ÷ 14 = 57%). National baseline is 37% across 60,823 indexed trials. Multi-site studies count once per state with a listed site, local access, not a national share.
An above-average open share means a larger fraction of this state's indexed portfolio is presently listed as Recruiting relative to the national registry mix. It does not measure clinic capacity, wait times, or the chance any individual will match a protocol. Sponsors report status on ClinicalTrials.gov; values can move between pulls when enrollment opens, pauses, or closes. Use the status chart above to see which non-recruiting statuses still dominate the same geography, then verify any study of interest on the registry before contacting a site. PlainTrial publishes the public export fields without rewriting sponsor-reported phase or status labels.
Read the late-versus-early phase tilt as a second lens on the same footprint: later-stage weight often concentrates where large multi-center programs list sites, while early-phase weight can reflect academic or first-in-human networks. Neither tilt is a quality score. Keep the national comparison in view so a large absolute recruiting count is not mistaken for an above-average share when the state's total portfolio is simply large.
What this means if you're in Puerto Rico
8 recruiting trials sit above the national open share: use that denser slot map carefully.
- Browse the 8 recruiting trials with sites in Puerto Rico, filtered to your area. Recruiting in Puerto Rico
- Cancer of Pancreas is the most-studied condition here: see its national picture. Cancer of Pancreas trials
- Compare research activity in other states before deciding where to look. All states
A trial is counted here when it lists at least one in-state site; always confirm eligibility and current status on ClinicalTrials.gov.
States With a Similar Recruiting Share
The closest states nationwide to Puerto Rico's 57% of trials currently recruiting.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered clinical trial within this state, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.